

Randomized phase II trial of deferasirox (Exjade•, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload

Antonio Piga Renzo Galanello Gian Luca Forni Maria Domenica Cappellini Raffaella Origa Antonietta Zappu Guido Donato Elena Bordone Antonella Lavagetto Laura Zanaboni Romain Sechaud Nicola Hewson John M Ford Herbert Opitz Daniele Alberti	Background and Objectives. Iron accumulatic blood transfusions and results in serious treatment to remove excess iron. Deferoxiand mortality although the administration are and mortality although the administration are are and mortality although the administration are and mortality although the administration are are and mortality although the administration are a Deferasirox (Exjade®, ICL670) is an oral of selectivity. In a phase II study, the tolerable pared with those of DFO in 71 adults with a Design and Methods. Patients were random or 20 mg/kg; n=24 in both groups) or DF weeks. Results. Both treatments were well tolerated due to drug-related adverse events. The recerate gastrointestinal disturbances was higg group, but these disturbances settled spop patients. Decreases in liver iron concentration 20 mg/kg/day and DFO groups; baseline variand 5.9 mg Fe/g dw, respectively, by week tion half-life of 8-16 hours, supporting its or Interpretation and Conclusions. Deferasirox tolerated and, at 20 mg/kg, showed simil decreases in LIC. Key words: iron chelation, deferasirox, thala deferoxamine. Haematologica 2006; 91:873-880 ©2006 Ferrata Storti Foundation	a complications in the absence of chelation amine (Desferal®, DFO) reduces morbidity schedule of slow, parenteral infusions sev- and negatively affects long-term outcome. chelator with high iron-binding potency and ility and efficacy of deferasirox were com- transfusional hemosiderosis. mized to receive once-daily deferasirox (10 0 (40 mg/kg, 5 days/week; n=23) for 48 ed and no patient discontinued deferasirox ported frequency of transient, mild to mod- ner in the deferasirox group than in the DFO ntaneously without dose interruption in all on (LIC) were comparable in the deferasirox alues of 8.5 and 7.9 mg Fe/g dw fell to 6.6 48. Deferasirox showed a plasma elimina- nce-daily administration.
From the Centro Microcitemie, Dipartimento di Scienze Pediatriche, Università di Torino, Italy (AP, GD, EB); Ospedale Regionale Microcitemie, Dipartimento di Scienze Biomediche e Biotecnologie, Università di Cagliari, Italy (RG, RO, AZ); Centro della Microcitemia e delle Anemie Congenite, Ospedale Galliera, Genova, Italy (GLF, AL); Centro Anemie Congenite, Ospedale Policlinico IRCCS, Università di Milano, Milan, Italy (MDC, LZ); Novartis Pharma AG, Basel, Switzerland (RS, NH, JMF, HO, DA). Correspondence: Antonio Piga, Divisione di Ematologia Pediatrica, Dipartimento Scienze Pediatriche e dell Adolescenza, Università di Torino, piazza Polonia 94, 10126 Torino, Italy. E-mail: antonio.piga@unito.it	Patients with chronic anemias such as tha- lassemia, sickle cell disease, congenital rare anemias and myelodysplastic syn- dromes require regular blood transfusions in order to improve both quality of life and sur- vival. Humans are unable to eliminate the iron released from the breakdown of transfused red blood cells and the excess iron is deposit- ed as hemosiderin and ferritin in the liver, spleen, endocrine organs and myocardium. The accumulation of toxic quantities of iron causes tissue damage and leads to complica- tions such as heart failure, diabetes, hypothy- roidism and liver failure. Morbidity and mor- tality in regularly-transfused thalassemia patients are due primarily to the effects of iron overload rather than to the underlying disease, with over half of all deaths attributable to car- diac complications.' Iron chelators mobilize tissue iron by forming soluble, stable complex- es that are then excreted in the feces and/or urine. More than 40 years of clinical experi- ence with deferoxamine (Desferal®, DFO) in iron-overloaded patients has established that chelation therapy, when given at an adequate dose, reduces iron-related complications and thereby improves quality of life and overall curving ²³ The prov oral bioavailability and	short plasma half-life of DFO necessitates par- enteral administration and prolonged infu- sions. The standard regimen to remove excess iron accumulated through regular transfusion is a subcutaneous (sc) infusion over 8-12 hours, on 3 to 7 days each week. This incon- venient schedule has a negative impact on compliance and eventually on long-term out- come, with some deaths being directly attrib- utable to poor compliance with therapy. ³⁻⁵ The need for an effective, well-tolerated, oral iron chelator has been recognized for many years but, despite much effort, few candidate mole- cules were suitable for development. The oral chelator deferiprone is licensed for use only in β -thalassemia patients when DFO treatment is either inadequate or contraindicated. Its restricted indication is due partly to the inci- dence of agranulocytosis (1%), which necessi- tates weekly neutrophil counts, and partly to the limited clinical data available regarding its efficacy. ⁶ Comparisons of deferiprone and DFO are largely based on retrospective analy- ses and additional well-designed prospective trials are needed to clarify the comparative effects of these agents. ⁷⁻¹² Combined treatment with DFO and deferiprone has shown addi- tional afficacy in patients who failed to

survival.^{2,3} The poor oral bioavailability and

tional efficacy in patients who failed to

respond satisfactorily to DFO or deferiprone treatment alone. $^{\scriptscriptstyle 13\text{-}17}$

Deferasirox (Exjade®, ICL670) is an N-substituted bishydroxyphenyl-triazole¹⁸ that was selected from more than 700 compounds as part of a rational drug development program. It represents a new class of tridentate iron chelators with a high specificity for iron.¹⁹ Selective and efficient mobilization of tissue iron has been demonstrated in animal models, with greater efficiency than with DFO.²⁰ In common with representatives from other classes of iron chelators, renal tubular nephropathy and lens opacities were noted in animal toxicology studies.¹⁹ Phase I clinical evaluation of deferasirox has confirmed that the compound is well tolerated at single oral doses of up to 80 mg/kg.^{21,22} Iron excretion occurs almost entirely in the feces and is dose-dependent, averaging 0.13, 0.34 and 0.56 mg/kg/day at deferasirox doses of 10, 20 and 40 mg/kg/day, respectively.22 The plasma half-life of 11-19 hours supported the once-daily oral dosing regimen which has been used in subsequent clinical trials.^{21,22}

This phase II study was carried out primarily to determine the safety and tolerability of deferasirox at doses of 10 and 20 mg/kg/day in comparison with a standard dose of DFO 40 mg/kg in patients with transfusional hemosiderosis. In addition, the 48-week treatment period provided the first opportunity for the collection and analysis of long-term pharmacokinetic data, which are of particular importance for a life-long medication. Changes in liver iron concentration (LIC) and serum ferritin were also assessed as measures of chelation efficacy.


Design and Methods


Quality control, quality assurance and monitoring

This trial was conducted in accordance with Good Clinical Practices, as outlined in the International Conference on Harmonization guidelines. Ethics Committee approval was obtained at each participating institution and written informed consent was obtained from all patients prior to participation in any study procedures. A Study Monitoring Committee comprising the four principal investigators (*AP, RG, GLF, MDC*) supervised the trial conduct, and made decisions regarding dose adjustment for individual patients. An independent Program Safety Board confidentially reviewed clinical and laboratory data on several occasions during this trial in order to ensure patient safety.

Patients

The study recruited 71 β -thalassemia patients aged \geq 18 years with transfusional hemosiderosis from four centers in Italy. Patients should have received a mean daily dose of DFO \geq 30 mg/kg 5 days/week (a hypothetical weekly dose of \geq 150 mg/kg) for \geq 4 weeks prior to entering the screening period and should have been regularly transfused. Patients were also required to have had at least two evaluations of serum ferritin values of 2000-8000 ng/mL documented during the preceding 12 months, or a superconducting quantum interference device (SQUID) LIC measurement of 5-15 mg Fe/g dw (performed in the previous year). For admission to the washout period, during





which DFO was discontinued (Figure 1), the LIC was required to be 5-15 mg Fe/g dw. Average post-transfusion hemoglobin levels were required to be 10.5-13.5 g/dL during the 12 months prior to enrollment, including one measurement during washout. Patients with an aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >250 U/L or a creatinine clearance <80 mL/minute were excluded, as were patients with hypertension and those with any degree of atrio-ventricular (A-V) block, clinically relevant QT interval prolongation, or those requiring treatment with digoxin or any drug that could induce prolongation of A-V conduction. Patients with a diagnosis of cataract or a previous history of clinically relevant ocular toxicity related to iron chelation were also excluded, as this was the first long-term deferasirox study and prospective data on these events were collected.

Study design

This was a multicenter, randomized, open-label study of 48 weeks' duration (Figure 1). The primary objective was to determine the safety and tolerability of deferasirox at daily doses of 10 and 20 mg/kg in comparison with a standard dose of DFO 40 mg/kg in patients with transfusional hemosiderosis. Secondary objectives included evaluation of the effects of deferasirox on LIC, serum ferritin, serum iron, transferrin and transferrin saturation. Other key aims were to explore an effective dose titration strategy that would allow deferasirox to be administered at doses that depleted or maintained iron load according to individual requirements and to evaluate the pharmacokinetic profile of deferasirox. The open-label design was considered appropriate in view of the differences in the treatment regimens and the fact that any potential bias would be counteracted by the objective nature of the efficacy parameters employed. During the 14-day run-in period, eligible patients had their usual DFO therapy adjusted to 40 mg/kg given on 5 consecutive days each week. Baseline LIC values were determined towards the end of the screening period. On day -5, patients were admitted to the study site to receive a blood transfusion to achieve a target hemoglobin level of \geq 13 g/dL prior to commencing study treatment. After a DFO washout period of 5 days, patients were randomized in a 1:1:1 ratio to receive either once-daily deferasirox (10 or 20 mg/kg) or DFO (40 mg/kg on 5 consecutive days per week). Randomization was performed using a validated system that generates an automated random assignment of numbers to treatment groups. Daily doses of deferasirox were prepared using 250 mg tablets which were divisible into four parts. The correct number of tablets was dispersed in a glass of noncarbonated mineral water, stirred and ingested 30 minutes before breakfast. DFO doses were prepared as a 10% solution using commercially available vials of 500 or 2000 mg dry powder. Subcutaneous infusion was performed using a Microject Crono[®] pump over 8-12 hours for 5 consecutive days each week. The study protocol allowed for dose adjustment within the range of 5-40 mg/kg/day in the deferasirox groups and 20-50 mg/kg in the DFO group. Depending on the response of each patient, assessed primarily using the change in LIC at three consecutive determinations, dose increases or decreases were made by ±5 or $\pm 10 \text{ mg/kg}$ in the deferasirox groups and by $\pm 10 \text{ mg/kg}$ in the DFO group. Dose reductions were performed if the decrease in LIC was extrapolated to fall below 2 mg Fe/g dw within the next 12 weeks and dose increases were prescribed if an increasing trend in LIC was noted. Dose adjustments were decided on a case-by-case basis in joint consultation between the Study Monitoring Committee and the sponsor. Patients continued to receive regular transfusions throughout the study. At the end of the study, patients, including those who were originally randomized to DFO, were offered the option of continuing therapy with deferasirox during a non-comparative extension phase. The results of this phase of the study will be reported separately.

Safety assessments

Laboratory tests, including evaluation of blood indices, liver and renal function, serum electrolytes, copper and zinc, were performed at baseline and at 2-weekly intervals throughout the study. All laboratory parameters were measured at a central laboratory (EXACTA Clinical Trials Services, Verona, Italy). Second void urine samples were collected for measurement of N-acetyl- β -glucosaminidase and an aliquot of urine was alkalinized for measurement of β -2 microglobulin. An ophthalmology examination, including a slit lamp examination of the lens and retinal fundoscopy, was performed every 2 weeks. Audiometry, ECG and liver ultrasonography were carried out every 3 months. Adverse events were recorded at each study visit and the severity of each adverse event was graded as mild, moderate or severe. A serious adverse event was defined as a medically significant event that was either fatal or lifethreatening, required surgical intervention, prolonged hospitalization or resulted in persistent disability. All adverse events and serious adverse events were assessed by the investigator for a possible relationship to the study drug. Adverse events were ranked according to incidence in the deferasirox 20 mg/kg/day treatment group.

Efficacy assessments

The efficacy of iron chelation was evaluated by determining changes in LIC, as this was considered to be the most robust indicator of total body iron.²³ To avoid the need for invasive liver biopsy, LIC was measured noninvasively by biomagnetic susceptometry using a low crit-

ical temperature (low-TC) superconducting quantum interference device (SQUID) biomagnetometer, which allows the measurement of the paramagnetic susceptibility of the iron stored in the liver as hemosiderin and ferritin. In patients with iron overload, the results of biomagnetic susceptometry measurements of hepatic non-heme iron have been reported to be strongly correlated with those obtained by conventional analysis of liver biopsy.²⁴ The reliability of this methodology is supported by early studies that showed a good correlation between biomagnetic liver susceptometry and liver biopsy determinations of LIC.²⁵⁻²⁷ All biomagnetic liver susceptometry evaluations were performed at the Ospedale Regina Margherita, University of Turin, Italy. LIC was determined at screening and then every 12 weeks during treatment and at the end of the study. LIC values derived from magnetic susceptometry as milligrams of iron per gram of liver tissue (wet weight) were multiplied by a factor of 3.33 to provide values per gram of liver tissue dry weight (mg Fe/g dw; the conventional units used for LIĆ).¹⁸ Responders to chelation were defined as patients exhibiting a >10% fall in LIC (mg Fe/g dw) in the end-of-study biomagnetic susceptometry assessment in comparison to baseline.²⁸

During the study, markers of iron metabolism (serum ferritin, serum iron, serum transferrin and transferrin saturation) were analyzed by a central laboratory (EXACTA Clinical Trials Services, Verona, Italy). The transferrin saturation was calculated from the serum iron and the transferrin concentrations. Urinary iron excretion was determined in 24-hour urine collections in ten patients taking deferasirox (five in each dose group) who also underwent blood sampling for pharmacokinetic analyses. Urinary iron excretion was measured using atomic absorption spectrometry.

Pharmacokinetic evaluation

The pharmacokinetic profile of deferasirox was assessed in a subpopulation of ten patients receiving deferasirox (five from each dose group). Blood samples were taken for this purpose at eight time-points during the study, one on day 1 after the first dose and seven during the steady state, and included collection intervals from pre-dose up to 24 hours after dose administration. Trough blood samples (taken 24 hours after the previous dose and immediately prior to the next dose) were taken for all patients, initially after 2 weeks of treatment, then every 4 weeks during the first 3 months of the study and subsequently every 12 weeks. The specific determination of the deferasirox and its iron complex Fe-[deferasirox]² in plasma was performed using high performance liquid chromatography with UV detection. The lower limits of quantification were 1.34 μ mol/L for deferasirox and 0.314 µmol/L for Fe-[deferasirox]².²⁹ Standard non-compartmental pharmacokinetic parameters (area under the curve, Cmax, tmax and half-life) were derived from the plasma concentrations of deferasirox and Fe-[deferasirox]².

Results

Patients' baseline characteristics

There was a preponderance of females in each treatment group (Table 1) and overall there were only 26 males among the 71 patients in the study. Apart from two individuals with β -thalassemia intermedia, both of whom received deferasirox, all patients had β -thalassemia major. The treatment groups were reasonably comparable with respect to medical history although no patient in the deferasirox 10 mg/kg/day group had either hypothyroidism or a history of hepatitis B infection. Approximately 50% of patients had undergone splenectomy.

Dosing of study drugs

The average daily dose of the study drug over the 48 weeks of treatment was close to the randomized dose in each of the treatment groups (Table 2). By the end of the study, a total of 35 dose adjustments had been performed in 31 of the 69 patients who had had at least one LIC assessment by biomagnetic liver susceptometry. Dose increases were implemented on average after 31 weeks of treatment (range 22-43 weeks), as dictated by the requirement of having LIC values from at least three consecutive biomagnetic liver susceptometry evaluations before dose adjustments were made. Among the treatment groups, dose increases were performed most frequently in patients randomized to deferasirox 10 mg/kg/day and least often in patients receiving DFO. No patient received a deferasirox dose greater than 30 mg/kg/day during the study period. Although one-third of the study population had dose interruptions due to adverse events, with the majority of these interruption occurring in the deferasirox 20 mg/kg/day group, all but three patients resumed therapy at the original dose. Infections were the most frequent cause of dose interruption during the study but no between-group differences were apparent in the frequency of these episodes. The duration of patient exposure to the study drugs is summarized in Table 2; no relevant differences between the treatment groups were observed.

Safety and tolerability

There were no deaths during the study. Four patients (two each in the deferasirox 20 mg/kg/day and DFO groups) were withdrawn prematurely from the study, three due to adverse events and one due to an unsatisfactory therapeutic effect. In one patient receiving DFO, the adverse events leading to discontinuation (arthralgia, headache and fever) were suspected by the investigator to be study drug-related. The other adverse events resulting in withdrawal from the study comprised arrhythmia and cardiac failure in a patient receiving DFO, and trauma due to a road traffic accident in a patient on deferasirox 20 mg/kg/day; neither was considered study drug-related. The patient withdrawn due to unsatisfactory therapeutic effect was randomized to deferasirox 20 mg/kg/day but the dose was reduced to 10 mg/kg/day on day 85 when a fall in LIC from 5.2 to 2.6 mg Fe/g dw was detected. On day 250, the LIC had increased again to 4.5 mg Fe/g dw. The patient was also noted to have QTc prolongation. Since this was an exclusion criterion for study participation, and given the limited clinical experience with deferasirox available at that time, dose re-escalation to 20 mg/kg/day was considered inappropriate and the study drug was therefore discontinued. Adverse events irrespective of presumed drug relationship occurring in more than

Table 1. Patients' baseline characteristics.

1	Deferasirox	Deferasirox	DFO
	10 mg/kg/day	20 mg/kg/day	40 mg/kg
	(n=24)	(n=24)	(n=23)
Mean age in years (range) Male/female Mean height in cm (± SD) Mean weight in kg (± SD) Underlying disease β-thalassemia major β-thalassemia intermedia* Medical history Splenectomy Hypogonadism (male or female) Hypothyroidism (acquired) Hepatitis B Hepatitis C [†] Cardiac disorder	23.7 (17-33) 6/18 155.6 (8.5) 52.4 (7.5) 23 1 8 10 0 0 7 4	25.6 (19-50)10/14157.0 (9.1)50.7 (9.3)23112125365	10/13 160.0 (9.3)

*Transfusion-dependent; †Anti-HCV-positive or HCV RNA-positive.

Table 2. Dosing details.

	Deferasirox 10 mg/kg/day (n=24)	Deferasirox 20 mg/kg/day (n=24)	DFO 40 mg/kg* (n=23)
Mean daily dose, mg/kg ± SD (range) Number of patients with dose adjustments	11.7±2.12 (8.5-14.7) 13	19.0±4.10 (10.4-25.6) 14	28.6±1.06 (26.6-31.6) 4
Number of dose adjustments Number of patients with dose interruptions due to an adverse event Dose at week 48' (mg/kg/day)	13 5	16 11	6 5
Discontinued 10 20 30 40 50	0 11 13 0	2 5 11 6	2 2 18 1
Mean duration of exposure in days (min-max) [‡]	345 (332-369)	332 (21-402)	318§ (13-392)

*DFO dose administered on 5 consecutive days per week; [†]Although adjustments of \pm 5 mg/kg were made, all adjustments were further altered such that final doses were all in steps of 10 mg/kg only; [‡]The availability of a LIC result by biomagnetic susceptometry marked the end of study and hence of the exposure period to the study drug. For patients for whom there was a delay in performing biomagnetic susceptometry, the duration of exposure to study drug was slightly longer than 48 weeks; [§]Days of participation in the study, as DFO was administered for only 5 days per week.

four patients in any treatment group are listed in Table 3. In general, the adverse events reported were typical of incidental medical problems that are encountered regularly in young adults. With the exception of nausea and vomiting, no marked differences were seen between the groups in the frequency, nature or severity of adverse events. However, differences became more apparent when adverse events with a suspected relationship to study drugs were considered. In patients randomized to receive deferasirox at doses of 10 and 20 mg/kg/day, nausea was seen in one and six patients and vomiting in none

and three patients, respectively, whereas no patients randomized to DFO experienced nausea and vomiting with a suspected relationship to DFO. However, the gastrointestinal adverse events were mild to moderate in severity and resolved spontaneously, generally within a few days and without dose interruption. One patient had a skin rash on two occasions with a suspected relationship to study drug. The first episode was a generalized rash, lasting from days 9-13, which settled with concomitant therapy. The second episode affected only the hands, lasted from days 25-57, and settled spontaneously. The study drug was not interrupted during either episode. There were no episodes of arthralgia in patients randomized to deferasirox. Serious adverse events, none of which was assessed as related to study drug, were reported in 12 of the 71 patients with a similar distribution among the treatment groups.

Isolated serum creatinine values above the upper limit of normal were detected in six patients (in three, one and two patients receiving deferasirox 10 mg/kg/day, deferasirox 20 mg/kg/day and DFO, respectively) during the study. However, no patient had consecutive measurements of serum creatinine above the upper limit of normal. Elevations of urinary β -2 microglobulin were detected in all treatment groups but were more frequent in patients receiving deferasirox 20 mg/kg/day. The elevations were transient and low-grade (<10-fold above the upper limit of normal) and tended to normalize despite continuation of the study drug. In three patients receiving deferasirox, treatment was temporarily interrupted and elevated values normalized within 7 to 10 days. In the two patients treated with deferasirox 20 mg/kg/day who experienced the highest elevations of β -2 microglobulin, the dose of study drug was reduced to 10 mg/kg/day as a precautionary measure, and this was followed by prompt normalization of the β -2 microglobulin levels. There were no consistent changes in levels of urinary N-acetyl-β-glucosaminidase. There were no episodes of neutropenia, agranulocytosis or thrombocytopenia in any of the treatment groups. Most patients had normal AST levels at baseline, though a relevant proportion (32%) had increased ALT, presumably reflecting liver damage due to chronic viral hepatitis and/or iron overload. No patient developed consistent or progressive elevations in transaminase levels. Serum copper and zinc levels fluctuated considerably during the study but no patient developed progressive decreases in these trace elements. No retinal findings, lens abnormalities or hearing losses were detected during regular ophthalmological and auditory testing.

Efficacy

All patients received regular transfusions during the study and the average daily volume of blood transfused was similar across treatment groups, as was the estimated total daily iron intake in mg/kg. Thus, the mean volume of blood given was 0.34 mL RBC/kg/day (range 0.20-0.48) and the mean daily iron intake was 0.37 mg/kg (range 0.22-0.52). Biomagnetic susceptometry assessments performed at the end of study showed average decreases in LIC of similar magnitude in the deferasirox 20 mg/kg/day and DFO groups (-2.1 and -2.0 mg Fe/g dw, respectively), when compared to the values obtained at baseline (Figure

 Table 3. Summary of adverse events reported in four or more patients in any treatment group, irrespective of presumed drug relationship.

Adverse event, n (%)	Deferasirox 10 mg/kg/day (n=24)	Deferasirox 20 mg/kg/day (n=24)	DFO 40 mg/kg (n=23)
Any adverse event	24 (100.0)	23 (95.8)	21 (91.3)
Back pain	8 (33.3)	10 (41.7)	8 (34.8)
Cough	5 (20.8)	10 (41.7)	4 (17.4)
Pyrexia	7 (29.2)	10 (41.7)	6 (26.1)
Abdominal pain	14 (58.3)	9 (37.5)	8 (34.8)
Rhinitis	7 (29.2)	9 (37.5)	6 (26.1)
Nausea	2 (8.3)	8 (33.3)	2 (8.7)
Vomiting	-	8 (33.3)	2 (8.7)
Asthenia	3 (12.5)	7 (29.2)	4 (17.4)
Headache	9 (37.5)	7 (29.2)	4 (17.4)
Pharyngitis	10 (41.7)	7 (29.2)	8 (34.8)
Diarrhea	7 (29.2)	6 (25.0)	6 (26.1)
Pharyngolaryngeal pain	5 (20.8)	6 (25.0)	6 (26.1)
Influenza	1 (4.2)	5 (20.8)	5 (21.7)
Allergic conjunctivitis		4 (16.7)	_
Dyspepsia	1 (4.2)	4 (16.7)	2 (8.7)
Influenza-like illness	7 (29.2)	3 (12.5)	4 (17.4)
Arthralgia	4 (16.7)	2 (8.3)	3 (13.0)
Vertigo	5 (20.8)	2 (8.3)	3 (13.0)
Urinary tract infection	4 (16.7)	1 (4.2)	1 (4.3)
Bronchitis	5 (20.8)	_	1 (4.3)

2). The number of responders, defined as patients exhibiting a >10% fall in LIC by the end of study, was equal in these two groups (Table 4). In contrast, deferasirox 10 mg/kg/day resulted in only a minimal fall in LIC of -0.4 mg Fe/g dw.

Over the study duration, mean serum ferritin levels remained stable in the deferasirox 20 mg/kg/day and DFO groups whereas there was a tendency for ferritin values to increase modestly over time in patients randomized to deferasirox 10 mg/kg/day (Figure 3). There were also no consistent changes in the levels of other markers of iron homeostasis (serum iron, transferrin and transferrin saturation).

Pharmacokinetics of deferasirox

The mean steady-state pharmacokinetic profiles of each deferasirox dose are presented in Figure 4A. The median time to reach the maximal concentrations (tmax, ss) of deferasirox ranged from 1 to 2 hours in both the 10 and 20 mg/kg/day dose groups. Table 5 summarizes the main pharmacokinetic parameters of deferasirox after administration of the first dose and on three selected days during the steady-state. The area under the curve (AUC) at steady state was dose-dependent and the elimination half-life for 10 and 20 mg/kg/day doses ranged from 7 to 16 hours. Trough concentrations of deferasirox and deferasirox-iron complex were almost always detectable in plasma over the entire dosing interval and were dose-related (Figure 4B). The exposure to the complex was about 5-20 times less than the exposure to deferasirox. The concentrations of deferasirox and deferasirox-iron complex increased in plasma from the first dose to steady state, but showed no further accumulation after multiple dosing during the 48week treatment period. Consistent with deferasirox's




Figure 2. Liver iron concentration at baseline and after 12, 24, 36 and 48 weeks of therapy with deferasirox or DFO (mean data \pm SD).




Figure 3. Serum ferritin levels over the course of the study (mean data \pm SD).

established mode of iron removal predominantly in the bile, urinary iron excretion levels were very low. The upper limits of urinary iron detected were $58\pm67 \mu$ moL/24h (mean \pm SD, data from four patients) and $40\pm29 \mu$ moL/24h (data from five patients) in the deferasirox 10 and 20 mg/kg/day groups, respectively.

Discussion

The primary objective of this study was to compare the safety and tolerability of daily oral doses of deferasirox (10 or 20 mg/kg) with a standard dose of DFO (40 mg/kg) over 48 weeks. During the safety evaluation, there was particular focus on toxicities that have been reported previously in the context of iron chelation therapy or that were seen during the preclinical toxicology evaluation of deferasirox. These included assessments of bone marrow, liver and kidney function, trace metal homeostasis, and screening for the development of lens opacities and high-frequency sensorineural hearing loss. Apart from differences related to the respective modes of administration, deferasirox was as well tolerated as DFO and no patient

Table 4. Percentage change in liver iron concentration between baseline and final visit.

Percentage change in liver iron concentration	Deferasirox 10 mg/kg/day (n=24) n (%)	Deferasirox 20 mg/kg/day (n=22) n (%)	DF0 40 mg/kg (n=21) n (%)
No change (±10%)	6 (25.0)	4 (18.2)	4 (19.0)
Fall (>10%)	11 (45.8)	16 (72.7)	16 (76.2)
Increase (>10%)	7 (29.2)	2 (9.1)	1 (4.8)

Liver iron concentration was measured non-invasively using a low-TC SQUID biomagnetometer.




Figure 4. A. Mean steady-state plasma concentrations (+SD) of deferasirox following a dose of 10 or 20 mg/kg/day. B. Mean trough concentrations (\pm SD) of deferasirox and iron complex Fe-[deferasirox]₂.

discontinued deferasirox due to drug-related adverse events. Transient, mild-to-moderate nausea, vomiting and abdominal pain were reported at a higher frequency in patients taking deferasirox, mainly at 20 mg/kg/day, but settled spontaneously without dose interruption in all patients. Other adverse events were as expected for this patient population, with no differences between the treatment groups. No cases of arthropathy, neutropenia, agranulocytosis or falling zinc levels were seen in patients receiving deferasirox. There were no deaths during the study and none of the reported serious adverse events

 Table 5. Main pharmacokinetic parameters of deferasirox in plasma after single and multiple deferasirox dose administration at selected visits.

	Deferasirox			
Day	Dose (mg/kg/day) (n. of subjects)	C _{max} (µmol/L) mean±SD	AUC0-24h (h.µmol/L) mean±SD	Half-life (h) mean±SD
1	10 (n=5)	41±17	354±186	8.9 [†] ±2.6
15	20 (n=5) 10 (n=4) 20 (n=5)	68±23 64±45 107±22	664±265 662±492 1279±208	7.2 [‡] ±1.8 9.0*±4.4 8.6 [‡] ±2.9
180	20 (n=3) 10 (n=6) 20 (n=4)	55 ± 44 99±32	486 ± 440 1262±358	0.0 ⁺ ±2.9 10.9 [†] ±6.3 9.8 [†] ±1.4
360	10 (n=4) 10 (n=1) 20 (n=8) 30 (n=1)	103 95±34 161	1202±338 1210 1001±627 1811	9.3 [±] ±2.3 7.4

Because a precise estimation of terminal elimination half-life was not possible, this parameter was not determined in 2^* , 3^t , 4^t subjects.

were suspected to be drug-related. No patient developed progressive increases in serum creatinine or consecutive measurements above the upper limit of normal during either the 48-week study or during the ongoing extension study in which the patients have received deferasirox at doses of 20-30 mg/kg/day for periods of up to 3 years (*Novartis, data on file*). Increases in urinary β -2 microglobulin were seen in all treatment groups but are of doubtful clinical relevance. The findings may relate to disturbances in renal tubular function in patients with thalassemia, which have been reported by several groups and which were attributed to the toxic effects of iron overload.³⁰⁻³²

Efficacy was assessed by measuring LIC, which is widely accepted to be a reliable indicator of total body iron.²³ The LIC was measured every 3 months using non-invasive biomagnetic susceptometry, since liver biopsy, even though it allows for a direct estimate of iron load, cannot be performed more frequently than once a year. Potential variability in LIC measurements was limited by performing all assessments at a single center. Although there was wide interpatient variability in LIC results in all treatment groups, there was a clear central tendency for LIC reduction in patients receiving deferasirox 20 mg/kg/day and for LIC maintenance over 48 weeks in patients randomized to 10 mg/kg/day. At the deferasirox dose of 20 mg/kg/day, the reduction in LIC was similar to that seen with DFO 40 mg/kg. In general, the data suggest that daily doses of deferasirox in the range of 20-30 mg/kg are required to deplete iron stores in the majority of regularly transfused thalassemia patients, whereas doses of 10 mg/kg/day might be suitable for the maintenance of stable iron levels. This conclusion is partly at variance with the results of a carefully conducted iron-balance study, which showed that the daily iron excretion measured 0.119 mg/kg in a small number of patients treated for 12 days at a daily dose of deferasirox 10 mg/kg.²² Since the average daily iron intake from blood transfusions in thalassemia patients is almost always greater than 0.3 mg/kg, the results of this earlier study suggest that a dose of deferasirox 10 mg/kg/day might be insufficient to maintain iron balance. Although dose modifications were allowed during the study, these generally occurred after 24-36 weeks of therapy due to the requirement of having LIC values from at least three consecutive biomagnetic liver susceptometry evaluations before making such modifications. The average daily dose of study drug was, therefore, close to the initial dose, being 11.7 and 19 mg/kg in patients randomized to deferasirox 10 and 20 mg/kg, respectively. As they were dictated by a rise in LIC, dose increases occurred in all treatment groups but were more frequent in patients treated with deferasirox 10 mg/kg/day. Dose decreases due to excessive falls in LIC occurred in two patients treated with deferasirox 20 mg/kg/day but in none treated with deferasirox 10 mg/kg/day or DFO.

Surprisingly, mean serum ferritin levels remained more or less constant throughout and did not mirror the clear trends in LIC that were observed across the treatment groups. The absence of concordance between LIC and serum ferritin in this study probably reflects the wide variability in ferritin levels at baseline, both within and between patients, coupled with the relatively small sample size. In contrast, a recently reported large phase III trial of deferasirox found robust parallel trends between LIC and serum ferritin levels.³³ In the relatively small study reported here, no consistent trends were noted in the levels of serum ferritin or other markers of iron overload including serum iron, transferrin and transferrin saturation. Emerging techniques for the non-invasive measurement of cardiac iron have added a new dimension to the analysis of efficacy of iron chelators. Such techniques were in their infancy at the time this preliminary study was designed, and measurement of cardiac iron load was not included. Current trials of deferasirox include analysis of cardiac iron load using T2* cardiovascular magnetic resonance.³⁴⁻³⁶ The results of these studies should cast light on the ability of deferasirox to remove excess iron from the heart, and provide valuable additional evidence on the clinical effects of deferasirox.

This study allowed the first evaluation of the pharmacokinetics of deferasirox after long-term administration. Importantly, trough plasma sampling indicated that the levels of deferasirox remained stable throughout the treatment period. Both deferasirox and Fe-[deferasirox]2 persisted at detectable levels in the blood over the entire dosing interval. Deferasirox was absorbed with a median tmax of about 12 hours post dose. The elimination half-life in plasma of deferasirox, which was around 7 to 16 hours and generally longer for the iron complex, allows for a convenient, once-daily administration schedule. In contrast, because of its short elimination half-life, deferiprone must be administered three times a day and strict compliance with this demanding schedule is unlikely. As reported in previous studies,^{21,22} urinary iron excretion was negligible indicating that this parameter is unsuitable for monitoring the efficacy of chelation therapy with deferasirox, contrasting with the utility of this approach for monitoring treatment with DFO. In conclusion, this phase II study over 48 weeks comparing two doses of deferasirox with a standard dose of DFO in β -thalassemia patients demonstrated that deferasirox 20 mg/kg given orally, once daily is as well-tolerated and efficacious in reducing LIC as DFO 40 mg/kg given by sc infusions for 5 days each week. The pharmacokinetic profile of deferasirox supports a convenient, once-daily, oral administration schedule, which offers the potential to improve compliance in comparison with that achieved with other available chelators. These preliminary results suggest that deferasirox is a well-tolerated, oral iron chelator with similar efficacy to DFO and, if confirmed in a larger number of patients, would represent a significant advance in the treatment of iron overload.

AP, HO, RS and DA designed the study. AP, RG, GLF, MDC, RO, AZ, GD, EB, AL, and LZ collected data. RS, NH, JF, HO and DA analyzed data. AP, RG, GF, MDC, RS, JF, HO and DA interpreted the results and jointly contributed to the first draft of the article. All authors reviewed and contributed revisions to the article and all authors gave final approval of the version to be published. Editorial assistance was provid-ed by Drs Ruth Tidey and Matthew Lewis.

RS, NH, IMF, HO, DA are employed by Novartis Pharma, whose product was studied in the present work. AP, RG, GLF, MDC received

References

- Borgna-Pignatti C, Rugolotto S, De Stefano P, Piga A, Di Gregorio F, Gamberini MR, et al. Survival and dis-
- Gamberini MK, et al. Survival and dis-ease complications in thalassemia major. Ann NY Acad Sci 1998;850:227-31. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee, A, et al. Survival in medically treated patients with homozygous β -thalassemia. N Engl J Med 1994;331:574-8. Oliviori NF, Brittanham CM, Iron cholat
- Olivieri NF, Brittenham GM. Iron-chelat-ing therapy and the treatment of tha-lassemia. Blood 1997;89:739-61. 3
- Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol 1996:95:26-36.
- Modell B, Khan M, Darlison M. Survival in β -thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000;355:2051-2.
- 6. European Medicines Agency. Ferriprox European Public Assessment Report, Scientific Discussion. www.emea.eu.int 2005.
- Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effective-ness of long-term therapy with the oral iron chelator deferiprone. Blood 2003; 7. 102:1583-7.
- Maggio A, D'Amico G, Morabito A, Capra M, Ciaccio C, Cianciulli P, et al. Deferiprone versus deferoxamine in
- Deteriptione versus deteroxamine in patients with thalassemia major: a ran-domized clinical trial. Blood Cells Mol Dis 2002;28:196-208. Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, et al. Long-term safety and effectiveness of iron-helation thera-9 and effectiveness of iron-chelation thera-
- py with deferiprone for thalassemia major. N Engl J Med 1998;339:417-23.
 Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003;88:489-96.
- 11. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with tha-lassemia major. Blood 2006;107:3733-7.
- Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, et al. Randomized controlled trial of deferi-prone or deferoxamine in β-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006; 107: 2729 44 3738-44.
- 13. Wonke B, Wright C, Hoffbrand AV.

Combined therapy with deferiprone and desferrioxamine. Br J Haematol 1998; 103:361-4.

- Athanassiou-Metaxa M, Kousi A, Hatzipantelis ES, Tsatra I, Ikonomou M, Perifanis V, et al. Combined chelation therapy with deferiprone and desferriox-amine in iron overloaded beta-thalassemia patients. Haematologica 2004; 89:ELT07.
- Kattamis A. Combined therapy with deferoxamine and deferiprone. Ann N Y Acad Sci 2005;1054:175-82. 15
- Alymara V, Bourantas D, Chaidos A, Bouranta P, Gouva M, Vassou A, et al. 16. Effectiveness and safety of combined iron-chelation therapy with deferoxam-ine and deferiprone. Hematol J 2004; 5: 475-9.
- Origa R, Bina P, Agus A, Crobu G, Defraia E, Dessi C, et al. Combined ther-17. apy with deferiprone and desferrioxamine in thalassemia major. Haematologica 2005;90:1309-14.
- Heinz U, Hegetschweiler K, Acklin P, Faller B, Lattmann R, Schnebli HP. 4-[3,5-Bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]-benzoic acid: a novel, efficient and selec-
- tive iron(iii) complexing agent. Angew Chem Int Ed Engl 1999;38:2568-70. Nick H, Acklin P, Lattmann R, Buehl-mayer P, Hauffe S, Schupp J, et al. Development of tridentate iron chelators: 19. from desferrithiocin to ICL670. Curr Med Chem 2003;10:1065-76.
- Nick H, Wong A, Acklin P, Faller B, Jin Y, Lattmann R, et al. ICL670A: preclinical profile. Adv Exp Med Biol 2002;509:185-20. 203
- Galanello R, Piga A, Alberti D, Rouan MC, Bigler H, Sechaud R. Safety, tolera-21. bility, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to β -thalassemia. J Clin Pharmacol 2003;43:565-72.
- Pharmacol 2003;43:565-72. Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld EJ, Sechaud R, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-con-trolled, dose-escalation trial. Lancet 2003; 361:1597-602. Angelucci E, Brittenham GM, McLaren CE, Ripalti M, Baronciani D, Giardini C, et al. Henstic iron concentration and total 22.
- 23. et al. Hepatic iron concentration and total body iron stores in thalassemia major. N
- Engl J Med 2000;343:327-31. Brittenham GM, Farrell DE, Harris JW, Feldman ES, Danish EH, Muir WA, et al. Magnetic-susceptibility measurement of human iron stores. N Engl J Med 1982; 24 307.1671-5
- 25. Brittenham GM, Badman DG. Non-

institutional research support, participated in scientific meetings and received lecture fees from Novartis Pharma. Although the authors do not own the data, they had full access to all data in this study and take complete responsibility for the integrity of the data, the accuracy of the data analysis and the final report.

Interim analyses of this study have been reported at the 44th American Society of Hematology Annual Meeting, Philadelphia, USA, 2002; BioIron World Congress on Iron Metabolism, Bethesda, USA, 2003; European Haematology Association Annual Meeting, Lyon, France, 2003; and Thalassaemia International Federation Annual Meeting, Palermo, Italy 2003.

Funding: This study was supported by Novartis Pharma AG, Switzerland.

Manuscript received July 6, 2005. Accepted May 3, 2006.

invasive measurement of iron: report of an NIDDK workshop. Blood 2003; 101: 15-9.

- Fischer R, Engelhardt R, Gabbe EE, Heinrich HC, Schmiegel WH, Wurbs D. 26. Liver iron quantification in the diagnosis and therapeutic control of iron loaded patients. In: Hoke M, Erne SN, Okada YC, Romani GL, eds. Biomagnetism: Clinical Aspects. Amsterdam: Elsevier 1992. p. 585-8. Jensen PD. Evaluation of iron overload.
- 27. Br J Haematol 2004;124:697-711.
- Fischer R. Liver iron susceptometry. In: Andrae W, Nowak H, editors. Magnetism In Medicine-A Handbook. Wiley-VHC, Berlin, 1998. p. 286-301. Rouan MC, Marfil F, Mangoni P, Sechaud 28.
- 29. R, Humbert H, Maurer G. Determination of a new oral iron chelator, ICL670, and its iron complex in plasma by high-per-formance liquid chromatography and ultraviolet detection. J Chromatogr B Biomed Sci Appl 2001;755:203-13.
- Aldudak B, Karabay BA, Noyan A, Ozel A, Anarat A, Sasmaz I, et al. Renal function in pediatric patients with β-tha-lassemia major. Pediatr Nephrol 2000; 15: 109-12.
- Koliakos G, Papachristou F, Koussi A, Perifanis V, Tsatra I, Souliou E, et al. 31. Urine biochemical markers of early renal dysfunction are associated with iron overload in β -thalassaemia. Clin Lab Haematol 2003;25:105-9.
- Sumboonnanonda A, Malasit P, Tan-phaichitr VS, Ong-ajyooth S, Sunthorn-chart S, Pattanakitsakul S, et al. Renal tubular function in β -thalassemia. Pediatr Nephrol 1998;12:280-3.
- Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, et al. A Phase III study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood 2006;107:3455-62. 33
- Porter JB, Tanner MA, Pennell DJ, Eleftheriou P. Improved myocardial T2* in transfusion dependent anemias receiv-ing ICL670 (Deferasirox). Blood 2005; 106:[abstract 3600]. Wood JC, Otto-Duessel M, Gonzales I, Aguilar M, Nick H, Shimada H, et al.
- 35 ICL670 removes cardiac iron in a gerbil model of iron overload. Blood 2005; 106:
- [abstract 2695]. Anderson LJ, Westwood MA, Holden S, Davis B, Prescott E, Wonke B, et al. Myocardial iron clearance during reversal 36. of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol 2004;127:348-